Oldroyd P, Oldroyd S, Meng M, Makwana R, Sanger G, Bulmer D, Malliaras GG and Owens RM (2024). Stretchable Device for Simultaneous Measurements of Contractility and Electrophysiology of Neuromuscular Tissue in The Gastrointestinal Tract. Wiley  Advanced Materials  10.1002/adma.202312735

Baidoo N, Sanger GJ and Belai A (2023). Histochemical and biochemical analysis of collagen content in formalin-fixed, paraffin embedded colonic samples. Elsevier  Methodsx  vol. 11, 10.1016/j.mex.2023.102416

Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA, Abbracchio MP, Abraham G, Agoulnik A, Alexander W, Al-Hosaini K, Bäck M, Baker JG, Barnes NM, Bathgate R, Beaulieu J-M, Beck-Sickinger AG, Behrens M, Bernstein KE, Bettler B, Birdsall NJM, Blaho V, Boulay F, Bousquet C and Bräuner-Osborne H (2023). The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors. Wiley  British Journal of Pharmacology  vol. 180, (S2) s23-s144. 10.1111/bph.16177

Andrews PLR, Golding JF and Sanger GJ (2023). An assessment of the effects of neurokinin1 receptor antagonism against nausea and vomiting: Relative efficacy, sites of action and lessons for future drug development. Wiley  British Journal of Clinical Pharmacology  vol. 89, (12) 3468-3490. 10.1111/bcp.15852

Makwana R and Sanger GJ (2023). Characterization of rat gastric myogenic contractions and modulation by oxytocin and arginine-vasopressin. Elsevier  European Journal of Pharmacology  vol. 955, 10.1016/j.ejphar.2023.175906

Davenport AP, Kitazawa T and Sanger G (2023). Motilin receptor in GtoPdb v.2023.1. University of Edinburgh  Iuphar/Bps Guide to Pharmacology Cite  vol. 2023, (1) 10.2218/gtopdb/f41/2023.1

Sanger GJ and Andrews PLR (2023). Review article: An analysis of the pharmacological rationale for selecting drugs to inhibit vomiting or increase gastric emptying during treatment of gastroparesis. Wiley  Alimentary Pharmacology & Therapeutics  vol. 57, (9) 962-978. 10.1111/apt.17466

Sanger GJ and Andrews PLR (2023). Efficacy and Safety of Drugs for Gastroparesis: Dopamine Receptor Antagonists Should Not Be Considered as a Single Pharmacologic Entity. Elsevier  Gastroenterology  vol. 165, (2) 520-521. 10.1053/j.gastro.2023.01.043

Sanger GJ and Makwana R (2023). Chapter 4A Commentary on The guts of the matter: Contribution of studies on smooth muscle to discoveries in pharmacology by Michael J. Rand and Frederick Mitchelson. Drug Action Haemodynamics and Immune Defence  Elsevier  10.1016/b978-0-323-85517-4.00002-3

Varangot-Reille C, Sanger GJ, Andrews PLR, Herranz-Gomez A, Suso-Martí L, de la Nava J and Cuenca-Martínez F (2022). Neural networks involved in nausea in adult humans: A systematic review. Elsevier  Autonomic Neuroscience  vol. 245, 10.1016/j.autneu.2022.103059

Baidoo N, Sanger GJ and Belai A (2022). The vulnerability of the human taenia coli to alterations in total collagen within the colon of the elderly. Elsevier  Acta Histochemica  vol. 124, (8) 10.1016/j.acthis.2022.151958

Makwana R, Crawley E, Straface M, Palmer A, Gharibans A, Devalia K, Loy J, O'Grady G, Andrews PLR and Sanger GJ (2022). Synergistic augmentation of rhythmic myogenic contractions of human stomach by arginine vasopressin and adrenaline: Implications for the induction of nausea. Wiley  British Journal of Pharmacology  vol. 179, (24) 5305-5322. 10.1111/bph.15943

Baidoo N, Sanger GJ and Belai A (2022). Effect of old age on the subpopulations of enteric glial cells in human descending colon. Wiley  Glia  vol. 71, (2) 305-316. 10.1002/glia.24272

Sanger GJ and Andrews PLR (2022). A proposal for rational drug class terminology: A gastrointestinal perspective. Wiley  British Journal of Pharmacology  vol. 179, (23) 5233-5234. 10.1111/bph.15946

Baidoo N, Crawley E, Knowles CH, Sanger GJ and Belai A (2022). Total collagen content and distribution is increased in human colon during advancing age. Public Library of Science (Plos)  Plos One  vol. 17, (6) 10.1371/journal.pone.0269689

Straface M, Koussai M-A, Makwana R, Crawley E, Palmer A, Cai W, Gharibans A, Adebibe M, Loy J, O’Grady G, Andrews PLR and Sanger GJ (2022). A multi-parameter approach to measurement of spontaneous myogenic contractions in human stomach: Utilization to assess potential modulators of myogenic contractions. Elsevier Bv  Pharmacological Research  vol. 180, 106247-106247. 10.1016/j.phrs.2022.106247

Perez-Ternero C, Aubdool AA, Makwana R, Sanger GJ, Stimson RH, Chan LF, Moyes AJ and Hobbs AJ (2022). C-type natriuretic peptide is a pivotal regulator of metabolic homeostasis. Proceedings of The National Academy of Sciences  Proceedings of The National Academy of Sciences of The United States of America  vol. 119, (13) 10.1073/pnas.2116470119

Sanger GJ (2022). Why is motilin active in some studies with mice, rats, and guinea pigs, but not in others? Implications for functional variability among rodents. Wiley  Pharmacology Research & Perspectives  vol. 10, (2) 10.1002/prp2.900

Andrews PLR, Williams RSB and Sanger GJ (2022). Anti-emetic effects of thalidomide: Evidence, mechanism of action, and future directions. Elsevier  Current Research in Pharmacology and Drug Discovery  vol. 3, 10.1016/j.crphar.2022.100138

Cai W, Makwana R, Straface M, Gharibans A, Andrews PLR and Sanger GJ (2021). Evidence for tetrodotoxin‐resistant spontaneous myogenic contractions of mouse isolated stomach that are dependent on acetylcholine. Wiley  British Journal of Pharmacology  vol. 179, (6) 1187-1200. 10.1111/bph.15685

Palmer A, Epton S, Crawley E, Straface M, Gammon L, Edgar MM, Xu Y, Elahi S, Chin-Aleong J, Martin JE, Bishop CL, Knowles CH and Sanger GJ (2021). Expression of p16 Within Myenteric Neurons of the Aged Colon: A Potential Marker of Declining Function. Frontiers in Neuroscience  vol. 15, 747067-747067. 10.3389/fnins.2021.747067

Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Davies JA, Abbracchio MP, Alexander W, Al-hosaini K, Bäck M, Barnes NM, Bathgate R, Beaulieu JM, Bernstein KE, Bettler B, Birdsall NJM, Blaho V, Boulay F, Bousquet C, Bräuner-Osborne H, Burnstock G, Caló G and Castaño JP (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. British Journal of Pharmacology  vol. 178, (S1) S27-S156. 10.1111/bph.15538

Davenport AP, Kitazawa T and Sanger G (2021). Motilin receptor in GtoPdb v.2021.2. University of Edinburgh  Iuphar/Bps Guide to Pharmacology Cite  vol. 2021, (2) 10.2218/gtopdb/f41/2021.2

Sanger GJ and Andrews PLR (2021). Emesis. Encyclopedia of Molecular Pharmacology  Springer Nature  10.1007/978-3-030-57401-7_161

Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt AL, Hartley RM, Hassaine G, Herrick-Davis K, Hovius R, Lacivita E, Lambe EK, Leopoldo M, Levy FO, Lummis SCR, Marin P, Maroteaux L, McCreary AC, Nelson DL, Neumaier JF, Newman-Tancredi A, Nury H and Roberts A (2020). International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. American Society For Pharmacology & Experimental Therapeutics (Aspet)  Pharmacological Reviews  vol. 73, (1) 310-520. 10.1124/pr.118.015552

Davis MP and Sanger GJ (2020). The Benefits of Olanzapine in Palliating Symptoms. Springer Nature  Current Treatment Options in Oncology  vol. 22, (1) 10.1007/s11864-020-00804-1

Makwana R, Loy J, Adebibe M, Devalia K, Andrews PL and Sanger GJ (2020). Copeptin, a surrogate marker of arginine8 vasopressin, has no ability to modulate human and mouse gastric motility. Elsevier  European Journal of Pharmacology  vol. 892, 10.1016/j.ejphar.2020.173740

Andrews PLR, Cai W, Rudd JA and Sanger GJ (2020). COVID‐19, nausea, and vomiting. Wiley  Journal of Gastroenterology and Hepatology  vol. 36, (3) 646-656. 10.1111/jgh.15261

Davenport AP and Sanger G (2020). Motilin receptor (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database. University of Edinburgh  Iuphar/Bps Guide to Pharmacology Cite  vol. 2020, (4) 10.2218/gtopdb/f41/2020.4

Sanger G and Andrews P (2020). Emesis. Encyclopedia of Molecular Pharmacology. , Editors: Offermanns S and Rosenthal W. In: Offermanns S., Rosenthal W. (Eds) Encyclopedia of Molecular Pharmacology. Springer, Cham  10.1007/978-3-030-21573-6_161-1

Straface M, Makwana R, Palmer A, Rombolà L, Aleong JC, Morrone LA and Sanger GJ (2020). Inhibition of Neuromuscular Contractions of Human and Rat Colon by Bergamot Essential Oil and Linalool: Evidence to Support a Therapeutic Action. Mdpi  Nutrients  vol. 12, (5) 10.3390/nu12051381

Choudhry N, Scott F, Edgar M, Sanger GJ and Kelly P (2020). Reversal of Pathogen-Induced Barrier Defects in Intestinal Epithelial Cells by Contra-pathogenicity Agents. Springer (Part of Springer Nature)  Digestive Diseases and Sciences  10.1007/s10620-020-06121-9

Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA, Abbracchio MP, Alexander W, Al-hosaini K, Bäck M, Beaulieu JM, Bernstein KE, Bettler B, Birdsall NJM, Blaho V, Bousquet C, Bräuner-Osborne H, Burnstock G, Caló G, Castaño JP, Catt KJ and Ceruti S (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology  vol. 176, (S1) S21-S141. 10.1111/bph.14748

Cibert-Goton V, Kung VWS, McGuire C, Hockley JRF, Tranter MM, Dogra H, Belai A, Blackshaw LA, Sanger GJ, Knowles CH, Araujo EJA, Winchester WJ and Bulmer DC (2019). Functional and anatomical deficits in visceral nociception with age: a mechanism of silent appendicitis in the elderly? Lippincott, Williams & Wilkins  Pain  vol. 161, (4) 773-786. 10.1097/j.pain.0000000000001764

Sanger GJ and Andrews PL (2019). Emesis. Drug Therapy For Gastrointestinal and Liver Diseases  Taylor & Francis  10.1201/9780429265433-3

Scott F, Elahi S, Adebibe M, Parampalli U, Mannur K, Góralczyk A and Sanger GJ (2019). Farnesoid X receptor ‐ a molecular predictor of weight loss after vertical sleeve gastrectomy? Wiley  Obesity Science & Practice  vol. 5, (3) 273-280. 10.1002/osp4.337

Ruffle JK, Patel A, Giampietro V, Howard MA, Sanger GJ, Andrews PLR, Williams SCR, Aziz Q and Farmer AD (2019). Functional brain networks and neuroanatomy underpinning nausea severity can predict nausea susceptibility using machine learning. Wiley  The Journal of Physiology  vol. 597, (6) 1517-1529. 10.1113/jp277474

SANGER GJ, BROAD J, KUNG V, Palmer A, ELAHI S, Karami A, Darreh-Shori T, Ahmed S, THAHA M, Carrol R, Chin-Aleong J, MARTIN J, Saffrey MJ and KNOWLES C (2018). Changes in neuromuscular structure and functions of human colon during ageing are region-dependent. Bmj Publishing Group  Gut  10.1136/gutjnl-2018-316279

SANGER GJ and Andrews PLR (2018). A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research. Front. Pharmacol. 9:913.  vol. 9, 10.3389/fphar.2018.00913

Alexander SPH, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA, Abbracchio MP, Aldrich R, Al-Hosaini K, Arumugam TV, Attali B, Bäck M, Barnes NM, Bathgate R, Beart PM, Becirovic E, Bettler B, Biel M and Birdsall NJ (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology  vol. 174, S1-S16. 10.1111/bph.13882

Sanger GJ (2017). Actions of Drugs in the Gastrointestinal Tract. Pharmacology For Chemists: Drug Discovery in Context  Royal Society of Chemistry (Rsc)  10.1039/bk9781782621423-00292

Alexander SP, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA and Collaborators C (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes. Wiley  British Journal of Pharmacology  vol. 174, (Suppl Suppl 1) s272-s359. 10.1111/bph.13877

Liszt KI, Ley JP, Lieder B, Behrens M, Stöger V, Reiner A, Hochkogler CM, Köck E, Marchiori A, Hans J, Widder S, Krammer G, Sanger GJ, Somoza MM, Meyerhof W and Somoza V (2017). Caffeine induces gastric acid secretion via bitter taste signaling in gastric parietal cells. Proceedings of The National Academy of Sciences  vol. 114, (30) E6260-E6269. 10.1073/pnas.1703728114

Sanger GJ and Pasricha PJ (2017). Investigational drug therapies for the treatment of gastroparesis. Taylor & Francis  Expert Opin Investig Drugs  vol. 26, (3) 331-342. 10.1080/13543784.2017.1288214

Sanger GJ, Broad J, Callaghan B and Furness JB (2016). Ghrelin and Motilin Control Systems in GI Physiology and Therapeutics. Springerlink  10.1007/164_2016_104

McGuire C, Boundouki G, Hockley JR, Reed D, Cibert-Goton V, Peiris M, Kung V, Broad J, Aziz Q, Chan C, Ahmed S, THAHA MA, Sanger GJ, Blackshaw LA, Knowles CH and BULMER DCE (2016). Ex vivo study of human visceral nociceptors., Editors: El-Omar E and Grady W. Bmj Publishing Group Ltd.  Gut  1-11. 10.1136/gutjnl-2016-311629

Broad J, Maurel D, Kung VWS, Hicks GA, Schemann M, Barnes MR, Kenakin TP, Granier S and Sanger GJ (2016). Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design. Springer Nature  Scientific Reports  vol. 6, (1) 10.1038/srep30797

Sanger GJ (2016). Chronic constipation: improved understanding offers a new therapeutic approach. J Physiol  vol. 594, (15) 4085-4087. 10.1113/JP272560

Hellström PM, Tack J, Johnson LV, Hacquoil K, Barton ME, Richards DB, Alpers DH, Sanger GJ and Dukes GE (2016). The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. British Journal of Pharmacology  vol. 173, (11) 1768-1777. 10.1111/bph.13475

Broad J, Takahashi N, Tajimi M, Sudo M, Góralczyk A, Parampalli U, Mannur K, Yamamoto T and Sanger GJ (2015). RQ-00201894: A motilin receptor agonist causing long-lasting facilitation of human gastric cholinergically-mediated contractions. Elsevier  Journal of Pharmacological Sciences  vol. 130, (2) 60-65. 10.1016/j.jphs.2015.11.004

Sanger GJ and Furness JB (2015). Ghrelin and motilin receptors as drug targets for gastrointestinal disorders. Springer Nature  Nature Reviews Gastroenterology & Hepatology  vol. 13, (1) 38-48. 10.1038/nrgastro.2015.163

Cibert-Goton V, Kung VW, Hockley JR, Blackshaw A, Knowles CH, Sanger GJ and Bulmer DC (2015). Tu1873 Evidence for Reduced Visceral Nociceptors Activation With Age During Appendicitis. Elsevier  Gastroenterology  vol. 148, (4) 10.1016/s0016-5085(15)33143-7

Broad J, Callaghan B, Sanger GJ, Brock JA and Furness JB (2015). Analysis of the ghrelin receptor-independent vascular actions of ulimorelin. Elsevier  European Journal of Pharmacology  vol. 752, 34-39. 10.1016/j.ejphar.2015.02.005

Farmer AD, Ban VF, Coen SJ, Sanger GJ, Barker GJ, Gresty MA, Giampietro VP, Williams SC, Webb DL, Hellström PM, Andrews PLR and Aziz Q (2015). Visually induced nausea causes characteristic changes in cerebral, autonomic and endocrine function in humans. Wiley  The Journal of Physiology  vol. 593, (5) 1183-1196. 10.1113/jphysiol.2014.284240

Broad J, Hughes F, Chin-Aleong J, Sifrim D and Sanger GJ (2014). Regionally dependent neuromuscular functions of motilin and 5-HT₄ receptors in human isolated esophageal body and gastric fundus. Neurogastroenterol Motil  vol. 26, (9) 1311-1322. 10.1111/nmo.12394

Broad J, Góralczyk A, Mannur K, Dukes GE and Sanger GJ (2014). Drugs acting at 5-HT4 , D2 , motilin, and ghrelin receptors differ markedly in how they affect neuromuscular functions in human isolated stomach. Neurogastroenterol Motil  vol. 26, (6) 851-861. 10.1111/nmo.12338

Broad J, Kung VW, Greene-Diniz R, Knowles CH and Sanger GJ (2014). Sa2043 Regionally-Specific Changes in Human Colonic Neuromuscular Activity With Advanced Age. Elsevier  Gastroenterology  vol. 146, (5) s-362. 10.1016/s0016-5085(14)61310-x

Farmer AD, Ban VF, Sanger GJ, Coen SJ, Andrews P and Azi Q (2014). Tu1811 Cortical & Physiological Responses to Visually Induced Motion Sickness. Elsevier  Gastroenterology  vol. 146, (5) s-850. 10.1016/s0016-5085(14)63087-0

Sanger GJ (2014). The relationship between symptom improvement and gastric emptying in the treatment of gastroparesis: remember the pharmacology. Am J Gastroenterol  vol. 109, (3) 444-445. 10.1038/ajg.2013.432

Sanger GJ (2014). Ghrelin and motilin receptor agonists: time to introduce bias into drug design. Neurogastroenterol Motil  vol. 26, (2) 149-155. 10.1111/nmo.12300

Andrews PLR and Sanger GJ (2014). Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol  vol. 722, 108-121. 10.1016/j.ejphar.2013.09.072

Andrews PLR and Sanger GJ (2014). Nausea and the quest for the perfect anti-emetic. European Journal of Pharmacology  vol. 722, 108-121. 10.1016/j.ejphar.2013.09.072

Kung V, Broad J, Knowles C and Sanger G (2014). Age related changes of neuromuscular functions in the human ascending colon. Neurogastroenterology and Motility  vol. 26, 34-34.

Sanger GJ (2013). Ghrelin and motilin receptor agonists: a long and winding misconception. Neurogastroenterol Motil  vol. 25, (12) 10.1111/nmo.12241

Sanger GJ, Wang Y, Hobson A and Broad J (2013). Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists. Br J Pharmacol  vol. 170, (7) 1323-1332. 10.1111/bph.12075

Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ, Abul-Hasn N, Anderson CM, Anderson CMH, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJM, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P and Calo G (2013). Overview. Wiley  British Journal of Pharmacology  vol. 170, (8) 1449-1458. 10.1111/bph.12444

Broad J, Kung VWS, Boundouki G, Aziz Q, De Maeyer JH, Knowles CH and Sanger GJ (2013). Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility. Br J Pharmacol  vol. 170, (6) 1253-1261. 10.1111/bph.12397

Sanger GJ, Broad J and Andrews PLR (2013). The relationship between gastric motility and nausea: gastric prokinetic agents as treatments. Eur J Pharmacol  vol. 715, (1-3) 10-14. 10.1016/j.ejphar.2013.06.031

Ng KS, Chua YC, Ban VF, Gresty M, Gampietro V, Coen SJ, Sanger GJ, Fitch KE, Heng RJ, Ruffle JK, Williams SC, Barker G, Andrews P and Aziz Q (2013). Su2110 Brain Processing of Visual Motion Induced Nausea in Healthy Humans. Elsevier  Gastroenterology  vol. 144, (5) 10.1016/s0016-5085(13)62071-5

Broad J and Sanger GJ (2013). The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Br J Pharmacol  vol. 168, (8) 1859-1867. 10.1111/bph.12077

Javid FA, Bulmer DC, Broad J, Aziz Q, Dukes GE and Sanger GJ (2013). Anti-emetic and emetic effects of erythromycin in Suncus murinus: role of vagal nerve activation, gastric motility stimulation and motilin receptors. Eur J Pharmacol  vol. 699, (1-3) 48-54. 10.1016/j.ejphar.2012.11.035

Sanger GJ, Broad J, Kung V and Knowles CH (2013). Translational neuropharmacology: the use of human isolated gastrointestinal tissues. Br J Pharmacol  vol. 168, (1) 28-43. 10.1111/j.1476-5381.2012.02198.x

Izzo AA (2013). Novel insights which may translate into treatments for irritable bowel syndrome. Frontiers  Frontiers in Pharmacology  vol. 4, 10.3389/fphar.2013.00160

Sanger GJ (2012). Motilin receptor neuropharmacology: revised understanding. Curr Opin Pharmacol  vol. 12, (6) 641-646. 10.1016/j.coph.2012.07.012

Sanger GJ (2012). New target profiling for gastrointestinal disorders: where are we going? Curr Opin Pharmacol  vol. 12, (6) 629-631. 10.1016/j.coph.2012.10.006

Webb D-L, Rudholm-Feldreich T, Gillberg L, Halim MA, Theodorsson E, Sanger GJ, Campbell CA, Boyce M, Näslund E and Hellström PM (2012). The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression. Springer Nature  Naunyn-Schmiedeberg\'s Archives of Pharmacology  vol. 386, (1) 41-49. 10.1007/s00210-012-0812-5

Broad J, Mukherjee S, Samadi M, Martin JE, Dukes GE and Sanger GJ (2012). Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol  vol. 167, (4) 763-774. 10.1111/j.1476-5381.2012.02009.x

Sung EZ, Arasaradnam RP, Jarvie EM, James S, Goodyear SJ, Borman RA, Snead D, SANGER GJ and Nwokolo CU (2012). Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function. Springer Netherlands  Mol Biol Rep  vol. 39, (12) 9989-9994. 10.1007/s11033-012-1866-7

Ng KS, Chua YC, Ban VF, Gresty M, Coen SJ, Sanger GJ, Williams SC, Barker G, Andrews P, Luu M, Ruffle JK, Heng RJ, Sims D, Brown E and Aziz Q (2012). 490 Studies of the Psychophysiological Markers and the Brain Processing of Nausea in Healthy Humans Using a Novel Virtual Reality Video. Elsevier  Gastroenterology  vol. 142, (5) s-105. 10.1016/s0016-5085(12)60395-3

Broad J, Andrews PL and Sanger GJ (2012). VASOPRESSIN CONTRACTS HUMAN ISOLATED STOMACH MUSCLE: POSSIBLE ROLE IN NAUSEA? Gut  vol. 61, A297-A298. 10.1136/gutjnl-2012-302514d.3

Ng KS, Coen SJ, Chua YC, Ban VF, Gresty MA, Sanger GJ, Williams SC, Barker GJ, Andrews PL, Imran M and Aziz Q (2012). STUDIES OF THE PSYCHOPHYSIOLOGICAL MARKERS AND THE BRAIN PROCESSING OF NAUSEA IN HEALTHY HUMANS USING A NOVEL VIRTUAL REALITY VIDEO. Gut  vol. 61, A317-A318. 10.1136/gutjnl-2012-302514d.51

Ng KS, Andrews P, Chua YC, Ban VF, Gresty M, Coen SJ, Sanger GJ, Williams SC, Barker G and Aziz Q (2012). Psychophysiological markers and the brain processing of nausea in healthy humans using a novel virtual reality video. Neurogastroenterology and Motility  vol. 24, 39-40.

Leming S, Broad J, Cozens SJ, Otterson M, Winchester W, Lee K, Dukes GE and Sanger GJ (2011). GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil  vol. 23, (10) 958-e410. 10.1111/j.1365-2982.2011.01770.x

Sanger GJ, Holbrook JD and Andrews PLR (2011). The translational value of rodent gastrointestinal functions: a cautionary tale. Trends Pharmacol Sci  vol. 32, (7) 402-409. 10.1016/j.tips.2011.03.009

Martin JE, Chowdhury AH, McElwaine S, Fikree A, Broad J, Knowles CH, Allen L, Bevan S, Burt E, Hymas AJ, Rowburrey PJ, Sanger GJ, Rahman MM, Thomas AA, Yiannakou Y, Cooper SC, Evagora CA, Levey PM, Cotter FE, Aziz Q, Elaine M, Pickersgill RW, Bainbridge K and Silk DB (2011). A Novel Phenotype of Glycogen Storage Disease Presenting as Gastrointestinal Neuromuscular Disease. Elsevier  Gastroenterology  vol. 140, (5) s-705. 10.1016/s0016-5085(11)62930-2

Hellström PM, Rudholm T, Gillberg L, Theodorsson E, Webb D, Sanger GJ and Naslund E (2011). Gastrin Receptor Antagonist YF476: Effects on Gastric Acid Secretion, Regulatory Peptides and Receptor Gene Expression in Rats. Elsevier  Gastroenterology  vol. 140, (5) s-730. 10.1016/s0016-5085(11)63034-5

Ng KS, Chua YC, Ban VF, Gresty M, Coen SJ, Sanger GJ, Williams SC, Barker G, Andrews P and Aziz Q (2011). Identifying Human Biomarkers of Nausea for Refining Animal Studies on Emesis. Elsevier  Gastroenterology  vol. 140, (5) s-368. 10.1016/s0016-5085(11)61503-5

Broad J, Hubball A, Souza M, Boundouki G, Knowles CH and Sanger GJ (2011). Serum but Not IgG From Patients With Chagas' Disease Relax Naive Human Colon Muscle Without Directly Interfering With Motor Nerve Functions. Elsevier  Gastroenterology  vol. 140, (5) s-282. 10.1016/s0016-5085(11)61134-7

Sanger GJ (2011). Effects of metoclopramide and domperidone on cholinergically mediated contractions of human isolated stomach muscle. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 37, (9) 661-664. 10.1111/j.2042-7158.1985.tb05108.x

Sanger GJ and Bennett A (2011). Regional differences in the responses to prostanoids of circular muscle from guinea-pig isolated intestine. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 32, (1) 705-708. 10.1111/j.2042-7158.1980.tb13043.x

Sanger GJ (2011). Three different ways in which 5-hydroxytryptamine can affect cholinergic activity in guinea-pig isolated ileum. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 37, (8) 584-586. 10.1111/j.2042-7158.1985.tb03076.x

Sanger GJ (2011). Activation of a myenteric 5-hydroxytryptamine-like receptor by metoclopramide. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 39, (6) 449-453. 10.1111/j.2042-7158.1987.tb03418.x

Sanger GJ, Hensby CN, Stamford IF and Bennett A (2011). Identification of arachidonic acid metabolites extracted from human uterus, and their effects on the isolated myometrium. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 33, (1) 607-610. 10.1111/j.2042-7158.1981.tb13879.x

SANGER GJ and BENNETT A (2011). Secoverine hydrochloride is a muscarinic antagonist in human isolated gastrointestinal muscle and myometrium. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 33, (1) 711-714. 10.1111/j.2042-7158.1981.tb13910.x

Bermudez J and Sanger GJ (2011). Prolonged anti-emetic activity and 5-HT3-receptor antagonism by BRL 46470 in conscious ferrets. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 46, (6) 520-521. 10.1111/j.2042-7158.1994.tb03843.x

Sanger GJ and Watt AJ (2011). Some mechanisms which may modulate noradrenaline release in guinea-pig isolated ileum. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 32, (1) 188-191. 10.1111/j.2042-7158.1980.tb12887.x

Bennett A, Stamford IF, Sanger GJ and Bloom SR (2011). The Effects of Various Peptides on Human Isolated Gut Muscle. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 44, (12) 960-967. 10.1111/j.2042-7158.1992.tb07074.x

Franks CM, Hardcastle J, Hardcastle PT and Sanger GJ (2011). Do 5-HT4 Receptors Mediate the Intestinal Secretory Response to 5-HT in Rat In-vivo? Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 47, (3) 213-218. 10.1111/j.2042-7158.1995.tb05781.x

Bingham S, King BF, Rushant B, Smith MI, Gaster L and Sanger GJ (2011). Antagonism by SB 204070 of 5-HT-evoked Contractions in the Dog Stomach: an In-vivo Model of 5-HT4 Receptor Function. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 47, (3) 219-222. 10.1111/j.2042-7158.1995.tb05782.x

Sanger GJ and Watt AJ (2011). The effect of PGE1 on peristalsis and on perivascular nerve inhibition of peristaltic activity in guinea-pig isolated ileum. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 30, (1) 762-765. 10.1111/j.2042-7158.1978.tb13388.x

Wardle KA, Furey G and Sanger GJ (2011). Pharmacological Characterization of the Vanilloid Receptor in the Rat Isolated Vas Deferens. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 48, (3) 285-291. 10.1111/j.2042-7158.1996.tb05918.x

Sanger GJ and Wardle KA (2011). Constipation Evoked by 5-HT3-Receptor Antagonism: Evidence for Heterogeneous Efficacy among Different Antagonists in Guinea-pigs. Oxford University Press (Oup)  Journal of Pharmacy and Pharmacology  vol. 46, (8) 666-670. 10.1111/j.2042-7158.1994.tb03879.x

Sanger GJ, Broad J and Alpers DH (2011). Translation of Motilin and Ghrelin Receptor Agonists into Drugs for Gastrointestinal Disorders. Peptide Drug Discovery and Development. Translational Research in Academia and Industry , Editors: Castanho MARB and Santos NC. Wiley Vch  10.1002/9783527636730.ch13

Sanger GJ, Chang L, Bountra C and Houghton LA (2010). Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. Therap Adv Gastroenterol  vol. 3, (5) 291-305. 10.1177/1756283X10369922

Falken Y, Hellstrom PM, Sanger GJ, Dewit O, Dukes G, Gryback P, Holst JJ and Naslund E (2010). Actions of prolonged ghrelin infusion on gastrointestinal transit and glucose homeostasis in humans. Neurogastroent Motil  vol. 22, (6) e192-e200. 10.1111/j.1365-2982.2009.01463.x

Ng KS, Chua YC, Gresty M, Marreddy U, Williams SC, Barker G, Andrews P, Sanger GJ, Ban VF, Wilson A, Chey SY and Aziz Q (2010). M2052 Identification of Psychophysiological Biomarkers of Nausea Using a Novel Visual Induction Method. Elsevier  Gastroenterology  vol. 138, (5) s-467. 10.1016/s0016-5085(10)62160-9

Sanger GJ, Hellström PM and Näslund E (2010). The hungry stomach: physiology, disease, and drug development opportunities. Front Pharmacol  vol. 1, 10.3389/fphar.2010.00145

Sanger GJ and Quigley EMM (2010). Constipation, IBs and the 5-HT4 Receptor: What Role for Prucalopride? Sage Publications  Therapeutic Advances in Gastrointestinal Endoscopy  vol. 3, 10.4137/cgast.s4136

Sanger GJ, Chang L, Bountra C and Houghton L (2010). Challenges and Prospects for Pharmacotherapy in Functional Gastrointestinal Disorders. Ther Adv Gastroenterol  vol. 3, (5) 291-305. 10.1177/1756283X10369922

Sanger GJ (2010). Gastrointestinal pharmacology: challenges ahead. Front Pharm  vol. 1, 4-4. 10.3389/fphar.2010.00004

Ferens DM, Yin L, Bron R, Hunne B, Ohashi-Doi K, Kitchener PD, Sanger GJ, Witherington J, Shimizu Y and Furness JB (2010). Functional and in situ hybridisation evidence that preganglionic sympathetic vasoconstrictor neurons express ghrelin receptors. Neuroscience  vol. 166, (2) 671-679. 10.1016/j.neuroscience.2010.01.001

Sanger GJ (2009). Translating 5-HT receptor pharmacology. Neurogastroenterol Motil  vol. 21, (12) 1235-1238. 10.1111/j.1365-2982.2009.01425.x

Mitchell NA, Pepperell E, Ociepka S, Brown JD, Witherington J, Tuladhar B, Sanger GJ, Lee K and Cellek S (2009). 5‐hydroxyindalpine, an agonist at the putative 5‐HT1P receptor, has no activity on human recombinant monoamine receptors but accelerates distension‐induced peristalsis in mouse isolated colon. Wiley  Neurogastroenterology & Motility  vol. 21, (7) 760-e48. 10.1111/j.1365-2982.2009.01275.x

Sung EZ, Jarvie E, James S, Menon VS, Borman RA, Snead D, Sanger GJ and Nwokolo CU (2009). W2074 Long-Term Consequences of Neo-Adjuvant Chemotherapy for Oesophago-Gastric Cancer On Gastric Contractility and Innervation. Elsevier  Gastroenterology  vol. 136, (5) a-786. 10.1016/s0016-5085(09)63631-3

Bassil AK, Bourdu S, Townson KA, Wheeldon A, Jarvie EM, Zebda N, Abuin A, Grau E, Livi GP, Punter L, Latcham J, Grimes AM, Hurp DP, Downham KM, Sanger GJ, Winchester WJ, Morrison AD and Moore GBT (2009). UDP-glucose modulates gastric function through P2Y14 receptor-dependent and -independent mechanisms. American Physiological Society  Ajp Gastrointestinal and Liver Physiology  vol. 296, (4) g923-g930. 10.1152/ajpgi.90363.2008

SANGER GJ, Westaway SM, Brown SL, Fell SCM, Johnson CM, MacPherson DT, Mitchell DJ, Myatt JW, Stanway SJ, Seal JT, Stemp G, Thompson M, Lawless K, MacKay F, Muir AI, Barford JM, Cluff C, Mahmood SR, Matthews KL, Mohamed S, Smith B, Stevens AJ, Bolton VJ and Jarvie EM (2009). Discovery of N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040): The first small molecule motilin receptor agonist clinical candidate. J Med Chem  vol. 52, 1180-1189. 10.1021/jm801332q

SANGER GJ, Westaway SM, Barnes AA, Macpherson DT, Muir AI, Jarvie EM, Bolton VN, Cellek S, Naslund E, Hellstrom PM, Borman RA, Unsworth WP, Matthews KL and Lee K (2009). GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterology and Motility  vol. 21, 657-666. 10.1111/j.1365-2982.2008.01270.x

Westaway SM and Sanger GJ (2009). The identification and rationale for drugs which act at the motilin receptor., Editors: Lawton G and Witty D. Progress in Medicinal Chemistry  vol. 48, 31-80. 10.1016/S0079-6468(09)04802-4

Westaway SM and Sanger GJ (2009). 2 The Identification of and Rationale for Drugs Which Act at The Motilin Receptor. Elsevier  10.1016/s0079-6468(09)04802-4

Bailey JM, Scott JS, Basilla JB, Bolton VJ, Boyfield I, Evans DG, Fleury E, Heightman TD, Jarvie EM, Lawless K, Matthews KL, McKay F, Mok H, Muir A, Orlek BS, Sanger GJ, Stemp G, Stevens AJ, Thompson M, Ward J, Vaidya K and Westaway SM (2009). The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor. Bioorg Med Chem Lett  vol. 19, (22) 6452-6458. 10.1016/j.bmcl.2009.09.027

Holbrook JD, Gill CH, Zebda N, Spencer JP, Leyland R, Rance KH, Trinh H, Balmer G, Kelly FM and Yusaf SP (2009). Characterisation of 5-HT3c, 5-HT3d and 5-HT3e receptor subunits: evolution, distribution and function. J Neurochem  vol. 108, (2) 384-396. 10.1111/j.1471-4159.2008.05775.x

Bassil AK, Taylor CM, Bolton VJN, Grey KM, Brown JD, Cutler L, Summerfield SG, Bruton G, Winchester WJ and Lee K (2009). Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology. Br J Pharmacol  vol. 158, (1) 252-258. 10.1111/j.1476-5381.2009.00155.x

Shafton AD, Sanger GJ, Witherington J, Brown JD, Muir A, Butler S, Abberley L, Shimizu Y and Furness JB (2008). Oral administration of a centrally acting ghrelin receptor agonist to conscious rats triggers defecation. Wiley  Neurogastroenterology & Motility  vol. 21, (1) 71-77. 10.1111/j.1365-2982.2008.01176.x

Witherington J, Abberley L, Bellenie BR, Boatman R, Collis K, Dean DK, Gaiba A, King NP, Shuker N, Steadman JGA, Takle AK, Sanger G, Butler S, McKay F, Muir A, Winborn K, Ward RW and Heightman TD (2008). Aryl sulphonyl amides as potent agonists of the growth hormone secretagogue (ghrelin) receptor. Elsevier  Bioorganic & Medicinal Chemistry Letters  vol. 19, (3) 684-687. 10.1016/j.bmcl.2008.12.042

Westaway SM, Brown SL, Conway E, Heightman TD, Johnson CN, Lapsley K, Macdonald GJ, MacPherson DT, Mitchell DJ, Myatt JW, Seal JT, Stanway SJ, Stemp G, Thompson M, Celestini P, Colombo A, Consonni A, Gagliardi S, Riccaboni M, Ronzoni S, Briggs MA, Matthews KL, Stevens AJ, Bolton VJ, Boyfield I, Jarvie EM, Stratton SC and Sanger GJ (2008). The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor. Elsevier  Bioorganic & Medicinal Chemistry Letters  vol. 18, (24) 6429-6436. 10.1016/j.bmcl.2008.10.072

Heightman TD, Conway E, Corbett DF, Macdonald GJ, Stemp G, Westaway SM, Celestini P, Gagliardi S, Riccaboni M, Ronzoni S, Vaidya K, Butler S, McKay F, Muir A, Powney B, Winborn K, Wise A, Jarvie EM and Sanger GJ (2008). Identification of small molecule agonists of the motilin receptor. Elsevier  Bioorganic & Medicinal Chemistry Letters  vol. 18, (24) 6423-6428. 10.1016/j.bmcl.2008.10.071

SUNG EZH, DA SILVA NF, GOODYEAR S, MCTERNAN PG, SANGER GJ and NWOKOLO CU (2008). Increased plasma ghrelin following infliximab in Crohn’s disease. Wiley  Alimentary Pharmacology & Therapeutics  vol. 29, (1) 83-89. 10.1111/j.1365-2036.2008.03850.x

Jarvie EM, Cellek S and Sanger GJ (2008). Potentiation by cholinesterase inhibitors of cholinergic activity in rat isolated stomach and colon. Elsevier  Pharmacological Research  vol. 58, (5-6) 297-301. 10.1016/j.phrs.2008.09.001

Sanger GJ (2008). 5-Hydroxytryptamine and the gastrointestinal tract: where next? Elsevier  Trends in Pharmacological Sciences  vol. 29, (9) 465-471. 10.1016/j.tips.2008.06.008

Sanger GJ, Bassil AK, Bolton VJ, Taylor CM, Gray K, Winchester WJ and Lee K (2008). T1381 Inhibition of Colonic Motility and Defecation By RS-127445 Suggests Involvement of the 5-HT2b Receptor in Large Bowel Physiology. Elsevier  Gastroenterology  vol. 134, (4) a-543. 10.1016/s0016-5085(08)62535-4

McRoberts JA, Ennes HS, Ameen VZ, Sanger GJ and Mayer EA (2008). W1751 Effects of Alosetron On CGRP Release from Colonic Tissue in Rats. Elsevier  Gastroenterology  vol. 134, (4) a-708. 10.1016/s0016-5085(08)63306-5

Malik NM, Moore GBT, Kaur R, Liu Y-L, Wood SL, Morrow RW, Sanger GJ and Andrews PLR (2008). Adaptive upregulation of gastric and hypothalamic ghrelin receptors and increased plasma ghrelin in a model of cancer chemotherapy-induced dyspepsia. Elsevier  Peptides  vol. 148, (1-3) 33-38. 10.1016/j.regpep.2008.03.005

Bolton VN, Bassil AK, Lee K and Sanger GJ (2008). Inhibition by tianeptine of neuronally mediated contractions in the rat isolated gastrointestinal tract. Elsevier  Pharmacological Research  vol. 57, (5) 339-343. 10.1016/j.phrs.2008.03.006

Sanger GJ and Lee K (2008). Hormones of the gut–brain axis as targets for the treatment of upper gastrointestinal disorders. Springer Nature  Nature Reviews Drug Discovery  vol. 7, (3) 241-254. 10.1038/nrd2444

Sanger GJ (2008). Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases. Elsevier  Drug Discovery Today  vol. 13, (5-6) 234-239. 10.1016/j.drudis.2007.10.024

Cellek S, Thangiah R, Jarvie EM, Vivekanandan S, Lalude O and Sanger GJ (2008). Synergy between 5-HT4 receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach. Neurogastroenterol Motil  vol. 20, 539-545. 10.1111/j.1365-2982.2007.01062.x

Bassil AK, Borman RA, Jarvie EM, McArthur-Wilson RJ, Thangiah R, Sung EZ, Lee K and Sanger GJ (2008). Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol  vol. 154, 126-135. 10.1038/bjp.2008.84

Sanger GJ and Lee K (2008). Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders. Nature Reviews Drug Discovery  vol. 7, 242-254.

Witherington J, Abberley L, Briggs MA, Collis K, Dean DK, Gaiba A, King PN, Kraus H, Shuker N, Steadman JGA, Takle AK, Sanger GJ, Wadsworth G, Butler S, McKay F, Muir A, Winborn K and Heightman TD (2008). Potent achiral agonists of the growth hormone secretatgogue (ghrelin) receptor. Part 2 – Lead Optimisation. Bioorg Med Chem Lett  vol. 18, 2203-2205. 10.1016/j.bmcl.2007.12.021

Olsson C, Holbrook JD, Bompadre G, Jönsson E, Hoyle C, Sanger GJ, Holmgren S and Andrews PLR (2008). Identification of genes for ghrelin and motilin receptors and a novel related gene in fish, and stimulation of intestinal motility in zebrafish (Danio rerio) by ghrelin and motilin. Gen Comparative Endocrinol  vol. 155, 217-226. 10.1016/j.ygcen.2007.05.016

Sanger GJ and Alpers DH (2008). Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil  vol. 20, 177-184. 10.1111/j.1365-2982.2008.01084.x

Sanger GJ (2007). Endocannabinoids and the gastrointestinal tract: what are the key questions? Wiley  British Journal of Pharmacology  vol. 152, (5) 663-670. 10.1038/sj.bjp.0707422

Heightman TD, Scott JS, Longley M, Bordas V, Dean DK, Elliott R, Hutley G, Witherington J, Abberley L, Passingham B, Berlanga M, de los Frailes M, Wise A, Powney B, Muir A, McKay F, Butler S, Winborn K, Gardner C, Darton J, Campbell C and Sanger G (2007). Potent achiral agonists of the ghrelin (growth hormone secretagogue) receptor. Part I: Lead identification. Elsevier  Bioorganic & Medicinal Chemistry Letters  vol. 17, (23) 6584-6587. 10.1016/j.bmcl.2007.09.067

Sanger GJ (2007). Gastrointestinal diseases. Elsevier  Drug Discovery Today Therapeutic Strategies  vol. 4, (3) 153-154. 10.1016/j.ddstr.2008.04.001

Borman RA and Sanger GJ (2007). Novel approaches and clinical opportunity for gastrointestinal prokinetic drugs. Elsevier  Drug Discovery Today Therapeutic Strategies  vol. 4, (3) 165-170. 10.1016/j.ddstr.2007.11.001

Shafton AD, Bogeski G, Kitchener PD, Sanger GJ, Furness JB and Shimizu Y (2007). Effects of NMDA receptor antagonists on visceromotor reflexes and on intestinal motility, in vivo. Wiley  Neurogastroenterology & Motility  vol. 19, (7) 617-624. 10.1111/j.1365-2982.2007.00942.x

Cellek S, Thangiah R, Bassil AK, Campbell CA, Gray KM, Stretton JL, Lalude O, Vivekanandan S, Wheeldon A, Winchester WJ, Sanger GJ, Schemann M and Lee K (2007). Demonstration of Functional Neuronal β3-Adrenoceptors Within the Enteric Nervous System. Elsevier  Gastroenterology  vol. 133, (1) 175-183. 10.1053/j.gastro.2007.05.009

Cellek S, Thangiah R, Bassil AK, Campbell CA, Gray KM, Stretton JL, Lalude O, Vivekanandan S, Wheeldon A, Winchester WJ, Sanger GJ and Schemann M (2007). WITHDRAWN: Demonstration of functional neuronal B3-adrenoceptors within the enteric nervous system. Elsevier  Gastroenterology  10.1053/j.gastro.2007.03.109

Dass NB, Bassil AK, North‐Laidler VJ, Morrow R, Aziz E, Tuladhar BR and Sanger GJ (2007). Neuromedin U can exert colon‐specific, enteric nerve‐mediated prokinetic activity, via a pathway involving NMU1 receptor activation. Wiley  British Journal of Pharmacology  vol. 150, (4) 502-508. 10.1038/sj.bjp.0707004

Jarvie EM, Laidler VJN, Corcoran S, Bassil A and Sanger GJ (2007). Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro. Wiley  British Journal of Pharmacology  vol. 150, (4) 455-462. 10.1038/sj.bjp.0707118

Bassil AK, Häglund Y, Brown J, Rudholm T, Hellström PM, Näslund E, Lee K and Sanger GJ (2007). Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract. Wiley  British Journal of Pharmacology  vol. 150, (1) 58-64. 10.1038/sj.bjp.0706969

Cellek S, Thangiah R, Bassil AK, Campbell CA, Gray KM, Stretton JL, Lalude O, Vivekanandan S, Wheeldon A, Winchester WJ, Sanger GJ, Schemann M and Lee K (2007). Demonstration of functional neuronal β₃-adrenoceptors within the enteric nervous system (vol 133, pg 175, 2007). Gastroenterology  vol. 133, (3) 1055-1055.

Sanger GJ, Tuladhar BR, Brown J, Aziz E, Sivakumar D and Furness JB (2007). Modulation of peristalsis by NK3 receptor antagonism in guinea-pig isolated ileum is revealed as intraluminal pressure is raised. Autonom Autocoid Pharmacol  vol. 27, 105-111. 10.1111/j.1474-8673.2007.00396.x

Dass NB, John AK, Bassil AK, Crumbley CW, Shehee WR, Maurio FP, Moore GBT, Taylor CM and Sanger GJ (2006). The relationship between the effects of short‐chain fatty acids on intestinal motility in vitro and GPR43 receptor activation. Wiley  Neurogastroenterology & Motility  vol. 19, (1) 66-74. 10.1111/j.1365-2982.2006.00853.x

Malik NM, Liu Y-L, Cole N, Sanger GJ and Andrews PLR (2006). Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats. Elsevier  European Journal of Pharmacology  vol. 555, (2-3) 164-173. 10.1016/j.ejphar.2006.10.043

Shimizu Y, Chang EC, Shafton AD, Ferens DM, Sanger GJ, Witherington J and Furness JB (2006). Evidence that stimulation of ghrelin receptors in the spinal cord initiates propulsive activity in the colon of the rat. Wiley  The Journal of Physiology  vol. 576, (1) 329-338. 10.1113/jphysiol.2006.116160

Sanger GJ and Andrews PLR (2006). Treatment of nausea and vomiting: Gaps in our knowledge. Elsevier  Autonomic Neuroscience  vol. 129, (1-2) 3-16. 10.1016/j.autneu.2006.07.009

Bassil AK, Dass NB and Sanger GJ (2006). The prokinetic-like activity of ghrelin in rat isolated stomach is mediated via cholinergic and tachykininergic motor neurones. Elsevier  European Journal of Pharmacology  vol. 544, (1-3) 146-152. 10.1016/j.ejphar.2006.06.039

Cellek S, John AK, Thangiah R, Dass NB, Bassil AK, Jarvie EM, Lalude O, Vivekanandan S and Sanger GJ (2006). 5‐HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Wiley  Neurogastroenterology & Motility  vol. 18, (9) 853-861. 10.1111/j.1365-2982.2006.00810.x

Liu Y-L, Malik NM, Sanger GJ and Andrews PLR (2006). Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Springer Nature  Cancer Chemotherapy and Pharmacology  vol. 58, (3) 326-333. 10.1007/s00280-005-0179-0

Malik NM, Moore GBT, Smith G, Liu Y-L, Sanger GJ and Andrews PLR (2006). Behavioural and hypothalamic molecular effects of the anti-cancer agent cisplatin in the rat: A model of chemotherapy-related malaise? Elsevier  Pharmacology Biochemistry and Behavior  vol. 83, (1) 9-20. 10.1016/j.pbb.2005.11.017

Sanger GJ, Tuladhar BR, Bueno L and Furness JB (2006). Defensive and pathological functions of the gastrointestinal NK3 receptor. Vascular Pharmacology  vol. 45, 215-220. 10.1016/j.vph.2005.08.026

Sanger GJ and Holzer P (2005). Endogenous Opioids and the Gastrointestinal Tract. Elsevier  Seminars in Colon and Rectal Surgery  vol. 16, (4) 197-199. 10.1053/j.scrs.2006.01.005

Bassil AK, Dass NB, Murray CD, Muir A and Sanger GJ (2005). Prokineticin-2, motilin, ghrelin and metoclopramide: Prokinetic utility in mouse stomach and colon. Elsevier  European Journal of Pharmacology  vol. 524, (1-3) 138-144. 10.1016/j.ejphar.2005.09.007

Rudd JA, Ngan MP, Wai MK, King AG, Witherington J, Andrews PLR and Sanger GJ (2005). Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Elsevier  Neuroscience Letters  vol. 392, (1-2) 79-83. 10.1016/j.neulet.2005.08.062

Liu Y-L, Malik N, Sanger GJ, Friedman MI and Andrews PLR (2005). Pica—A model of nausea? Species differences in response to cisplatin. Elsevier  Physiology & Behavior  vol. 85, (3) 271-277. 10.1016/j.physbeh.2005.04.009

King AG and Sanger GJ (2004). Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret. Elsevier  Neuroscience Letters  vol. 376, (1) 5-8. 10.1016/j.neulet.2004.11.015

Sanger GJ and Tuladhar BR (2004). The role of endogenous opioids in the control of gastrointestinal motility: predictions from in vitro modelling. Wiley  Neurogastroenterology & Motility  vol. 16, (s2) 38-45. 10.1111/j.1743-3150.2004.00556.x

Sanger GJ (2004). Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Wiley  British Journal of Pharmacology  vol. 141, (8) 1303-1312. 10.1038/sj.bjp.0705742

Shafton AD, Bogeski G, Kitchener PD, Lewis VA, Sanger GJ and Furness JB (2004). Effects of the peripherally acting NK3 receptor antagonist, SB‐235375, on intestinal and somatic nociceptive responses and on intestinal motility in anaesthetized rats. Wiley  Neurogastroenterology & Motility  vol. 16, (2) 223-231. 10.1111/j.1365-2982.2004.00501.x

O'Connor V, Genin A, Davis S, Karishma KK, Doyère V, De Zeeuw CI, Sanger G, Hunt SP, Richter-Levin G, Mallet J, Laroche S, Bliss TVP and French PJ (2004). Differential Amplification of Intron-containing Transcripts Reveals Long Term Potentiation-associated Up-regulation of Specific Pde10A Phosphodiesterase Splice Variants*. Elsevier  Journal of Biological Chemistry  vol. 279, (16) 15841-15849. 10.1074/jbc.m312500200

Dass NB, Hill J, Muir A, Testa T, Wise A and Sanger GJ (2003). The rabbit motilin receptor: molecular characterisation and pharmacology. Wiley  British Journal of Pharmacology  vol. 140, (5) 948-954. 10.1038/sj.bjp.0705505

Read KE, Sanger GJ and Ramage AG (2003). Evidence for the involvement of central 5‐HT7 receptors in the micturition reflex in anaesthetized female rats. Wiley  British Journal of Pharmacology  vol. 140, (1) 53-60. 10.1038/sj.bjp.0705399

Dass NB, Munonyara M, Bassil AK, Hervieu GJ, Osbourne S, Corcoran S, Morgan M and Sanger GJ (2003). Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin. Elsevier  Neuroscience  vol. 120, (2) 443-453. 10.1016/s0306-4522(03)00327-0

Bogeski G, Lean NP, Kitchener PD, Timar‐Peregrin A, Sanger GJ, Shafton AD and Furness JB (2003). Analysis of factors that determine the compliance of rat jejunum to distension in vivo. Wiley  Neurogastroenterology & Motility  vol. 15, (4) 417-425. 10.1046/j.1365-2982.2003.00423.x

Fioramonti J, Gaultier E, Toulouse M, Sanger GJ and Bueno L (2003). Intestinal anti‐nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Wiley  Neurogastroenterology & Motility  vol. 15, (4) 363-369. 10.1046/j.1365-2982.2003.00420.x

Hoyle CHV, Hill J, Sanger GJ and Andrews PLR (2003). Analysis of pancreatic polypeptide cDNA from the house musk shrew, Suncus murinus, suggests a phylogenetically closer relationship with humans than for other small laboratory animal species. Elsevier  Peptides  vol. 114, (2-3) 137-144. 10.1016/s0167-0115(03)00113-7

Medhurst A, Lawson S, Raval P, Sanger G, Newton R, Parsons A, Davey P, Bingham S, Case CP and Piercy V (2003). Molecular Approaches to the Study of Pain. Pain  Taylor & Francis  10.1201/9780203911259.pt3

Newton RA, Bingham S, Davey P, Medhurst AD, Piercy V, Raval P, Parsons AA, Sanger GJ, Case CP and Lawson SN (2003). Molecular Approaches to the Study of Pain. Pain  Taylor & Francis  10.1201/9780203911259-30

Génin A, French P, Doyère V, Davis S, Errington ML, Maroun M, Stean T, Truchet B, Webber M, Wills T, Richter‐Levin G, Sanger G, Hunt SP, Mallet J, Laroche S, Bliss TVP and O'Connor V (2003). LTP but not seizure is associated with up‐regulation of AKAP‐150. Wiley  European Journal of Neuroscience  vol. 17, (2) 331-340. 10.1046/j.1460-9568.2003.02462.x

Sanger GJ and Hicks GA (2002). Drugs targeting functional bowel disorders: insights from animal studies. Elsevier  Current Opinion in Pharmacology  vol. 2, (6) 678-683. 10.1016/s1471-4892(02)00228-x

Furness JB and Sanger GJ (2002). Gastrointestinal neuropharmacology: identification of therapeutic targets. Elsevier  Current Opinion in Pharmacology  vol. 2, (6) 609-611. 10.1016/s1471-4892(02)00231-x

Andrews PLR and Sanger GJ (2002). Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction. Elsevier  Current Opinion in Pharmacology  vol. 2, (6) 650-656. 10.1016/s1471-4892(02)00227-8

Furness JB and Sanger GJ (2002). Intrinsic nerve circuits of the gastrointestinal tract: identification of drug targets. Elsevier  Current Opinion in Pharmacology  vol. 2, (6) 612-622. 10.1016/s1471-4892(02)00219-9

Sanger GJ, Munonyara ML, Dass N, Prosser H, Pangalos MN and Parsons ME (2002). GABAB receptor function in the ileum and urinary bladder of wildtype and GABAB1 subunit null mice. Wiley  Autonomic and Autacoid Pharmacology  vol. 22, (3) 147-154. 10.1046/j.1474-8673.2002.00254.x

Timar‐Peregrin A, Kumano K, Khalil Z, Sanger GJ and Furness JB (2001). The relationship between propagated contractions and pseudoaffective changes in blood pressure in response to intestinal distension. Wiley  Neurogastroenterology & Motility  vol. 13, (6) 575-584. 10.1046/j.1365-2982.2001.00289.x

Newton RA, Bingham S, Case PC, Sanger GJ and Lawson SN (2001). Dorsal root ganglion neurons show increased expression of the calcium channel α2δ-1 subunit following partial sciatic nerve injury. Elsevier  Brain Research  vol. 95, (1-2) 1-8. 10.1016/s0169-328x(01)00188-7

Fedouloff M, Hossner F, Voyle M, Ranson J, Powles J, Riley G and Sanger G (2001). Synthesis and pharmacological activity of metabolites of the 5-HT4 receptor antagonist SB-207266. Elsevier  Bioorganic & Medicinal Chemistry  vol. 9, (8) 2119-2128. 10.1016/s0968-0896(01)00120-1

Medhurst AD, Lezoualc’h F, Fischmeister R, Middlemiss DN and Sanger GJ (2001). Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT-PCR. Elsevier  Brain Research  vol. 90, (2) 125-134. 10.1016/s0169-328x(01)00095-x

Rausch O, Newton RA, Bingham S, Macdonald R, Case CP, Sanger GJ, Lawson SN and Reith AD (2000). Nerve injury-associated kinase: a sterile 20-like protein kinase up-regulated in dorsal root ganglia in a rat model of neuropathic pain. Elsevier  Neuroscience  vol. 101, (3) 767-777. 10.1016/s0306-4522(00)00392-4

Hayes P, Meadows HJ, Gunthorpe MJ, Harries MH, Duckworth DM, Cairns W, Harrison DC, Clarke CE, Ellington K, Prinjha RK, Barton AJL, Medhurst AD, Smith GD, Topp S, Murdock P, Sanger GJ, Terrett J, Jenkins O, Benham CD, Randall AD, Gloger IS and Davis JB (2000). Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Wolters Kluwer  Pain  vol. 88, (2) 205-215. 10.1016/s0304-3959(00)00353-5

Sanger GJ, Yoshida M, Yahyah M and Kitazumi K (2000). Increased defecation during stress or after 5‐hydroxytryptophan: selective inhibition by the 5‐HT4 receptor antagonist, SB‐207266. Wiley  British Journal of Pharmacology  vol. 130, (3) 706-712. 10.1038/sj.bjp.0703367

Sanger GJ, Ellis ES, Harries MH, Tilford NS, Wardle KA and Benham CD (2000). Rank-order inhibition by ω-conotoxins in human and animal autonomic nerve preparations. Elsevier  European Journal of Pharmacology  vol. 388, (1) 89-95. 10.1016/s0014-2999(99)00830-4

Wood MD, Murkitt KL, Gager T, Ranson J and Sanger GJ (1999). Pharmacological characterisation of the human P2X4 receptor using the FLIPR. Pharmacology Reviews and Communications  vol. 10, (4) 341-347.

Newton RA, Bingham S, Davey PD, Medhurst AD, Piercy V, Raval P, Parsons AA, Sanger GJ, Case CP and Lawson SN (1999). Identification of differentially expressed genes in dorsal root ganglia following partial sciatic nerve injury. Elsevier  Neuroscience  vol. 95, (4) 1111-1120. 10.1016/s0306-4522(99)00515-1

Carpenter D, Meadows HJ, Brough S, Chapman G, Clarke C, Coldwell M, Davis R, Harrison D, Meakin J, McHale M, Rice SQJ, Tomlinson WJ, Wood M and Sanger GJ (1999). Site-specific splice variation of the human P2X4 receptor. Elsevier  Neuroscience Letters  vol. 273, (3) 183-186. 10.1016/s0304-3940(99)00653-9

Smith MI, Banner SE and Sanger GJ (1999). 5-HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3 receptor antagonism in conscious rats. Elsevier  Neuroscience Letters  vol. 271, (1) 61-64. 10.1016/s0304-3940(99)00513-3

Piercy V, Banner SE, Bhattacharyya A, Parsons AA, Sanger GJ, Smith SA and Bingham S (1999). Thermal, But Not Mechanical, Nociceptive Behavior is Altered in the Zucker Diabetic Fatty Rat and Is Independent of Glycemic Status. Elsevier  Journal of Diabetes and Its Complications  vol. 13, (3) 163-169. 10.1016/s1056-8727(99)00034-3

Sanger GJ (1999). Hypersensitivity and Hyperreactivity in the Irritable Bowel Syndrome: An Opportunity for Drug Discovery. Karger Publishers  Digestive Diseases  vol. 17, (2) 90-99. 10.1159/000016910

Reavill C, Hatcher JP, Lewis VA, Sanger GJ and Hagan J (1998). 5-HT4 receptor antagonism does not affect motor and reward mechanisms in the rat. Elsevier  European Journal of Pharmacology  vol. 357, (2-3) 115-120. 10.1016/s0014-2999(98)00564-0

SANGER , SMITH and WARDLE (1998). SB‐207266: 5‐HT4 receptor antagonism in human isolated gut and prevention of 5‐HT‐evoked sensitization of peristalsis and increased defaecation in animal models. Wiley  Neurogastroenterology & Motility  vol. 10, (4) 271-279. 10.1046/j.1365-2982.1998.00106.x

King FD, Gaster LM, Sanger GJ and Wardle KA (1998). Modulators of 5-HT functions in the treatment of Gastrointestinal Disorders. Trends in Drug Research II, Proceedings of The 11th Noordwijkerhout-Camerino Symposium  Elsevier  10.1016/s0165-7208(98)80056-1

Sanger GJ (1998). Therapeutic Applications of 5-HT4 Receptor Agonists and Antagonists. 5-Ht4 Receptors in The Brain and Periphery  Springer Nature  10.1007/978-3-662-05553-3_10

Wardle KA, Ranson J and Sanger GJ (1997). Pharmacological characterization of the vanilloid receptor in the rat dorsal spinal cord. Wiley  British Journal of Pharmacology  vol. 121, (5) 1012-1016. 10.1038/sj.bjp.0701199

Kennett GA, Bright F, Trail B, Blackburn TP and Sanger GJ (1997). Anxiolytic-like Actions of the Selective 5-HT4 Receptor Antagonists SB 204070A and SB 207266A in Rats. Elsevier  Neuropharmacology  vol. 36, (4-5) 707-712. 10.1016/s0028-3908(97)00037-3

SANGER GJ (1996). 5‐Hydroxytryptamine and functional bowel disorders. Wiley  Neurogastroenterology & Motility  vol. 8, (4) 319-331. 10.1111/j.1365-2982.1996.tb00270.x

Banner SE, Smith MI, Bywater D, Gaster LM and Sanger GJ (1996). Increased defaecation caused by 5-HT4 receptor activation in the mouse. Elsevier  European Journal of Pharmacology  vol. 308, (2) 181-186. 10.1016/0014-2999(96)00296-8

Wardle KA, Bingham S, Ellis ES, Gaster LM, Rushant B, Smith MI and Sanger GJ (1996). Selective and functional 5‐hydroxytryptamine4 receptor antagonism by SB 207266. Wiley  British Journal of Pharmacology  vol. 118, (3) 665-670. 10.1111/j.1476-5381.1996.tb15452.x

GASTER LM, JOINER GF, KING FD, WYMAN PA, SUTTON JM, BINGHAM S, ELLIS ES, SANGER GJ and WARDLE KA (1996). ChemInform Abstract: N‐((1‐Butyl‐4‐piperidinyl)methyl)‐3,4‐dihydro‐2H‐(1,3)oxazino(3,2‐a) indole‐10‐carboxamide Hydrochloride: The First Potent and Selective 5‐ HT4 Receptor Antagonist Amide with Oral Activity. Wiley  Cheminform  vol. 27, (14) no-no. 10.1002/chin.199614179

Sanger GJ and Twycross R (1996). Making Sense of Emesis, Pruritus, 5-HT and 5-HT3 Receptor Antagonists. Taylor & Francis  Progress in Palliative Care  vol. 4, (1) 7-8. 10.1080/09699260.1996.11746729

Gaster LM, Joiner GF, King FD, Wyman PA, Sutton JM, Bingham S, Ellis ES, Sanger GJ and Wardle KA (1995). N-[(1-butyl-4-piperidinyl)methyl]-3,4dihydro-2H-[1,3]oxazino[3,2- a]indole10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity. American Chemical Society (Acs)  Journal of Medicinal Chemistry  vol. 38, (24) 4760-4763. 10.1021/jm00024a002

Banner SE, Carter M and Sanger GJ (1995). 5-Hydroxytryptamine3 receptor antagonism modulates a noxious visceral pseudoaffective reflex. Elsevier  Neuropharmacology  vol. 34, (3) 263-267. 10.1016/0028-3908(94)00159-p

Banner SE and Sanger GJ (1995). Differences between 5‐HT3 receptor antagonists in modulation of visceral hypersensitivity. Wiley  British Journal of Pharmacology  vol. 114, (2) 558-562. 10.1111/j.1476-5381.1995.tb13263.x

Wardle KA, Ellis ES, Baxter GS, Kennett GA, Gaster LM and Sanger GJ (1994). The effects of SB 204070, a highly potent and selective 5‐HT4 receptor antagonist, on guinea‐pig distal colon. Wiley  British Journal of Pharmacology  vol. 112, (3) 789-794. 10.1111/j.1476-5381.1994.tb13148.x

Sanger GJ and Gaster LM (1994). Overview Central & Peripheral Nervous System: 5-HT4 receptor antagonists. Taylor & Francis  Expert Opinion On Therapeutic Patents  vol. 4, (4) 323-332. 10.1517/13543776.4.4.323

Gaster LM and Sanger GJ (1994). SB-204070: 5-HT4 receptor antagonists and their potential therapeutic utility. Portico  Drugs of The Future  vol. 19, (12) 10.1358/dof.1994.019.12.278844

Sanger GJ and Gaster LM (1994). 5-HT4 receptor antagonists. Expert Opinion On Therapeutic Patents  vol. 4, (4) 323-334.

Bingham S, Blower PR, Davey PT, King PD, Sanger GJ, Wardle KA and Nishioka Y (1994). Differences between the anti-emetic efficacies of the 5-HT3 receptor antagonists granisetron and azasetron in the conscious ferret. Pharmacometrics  vol. 47, (1) 21-28.

Gaster LM, Jennings AJ, Joiner GF, King FD, Mulholland KR, Rahman SK, Starr S, Wyman PA, Wardle KA and Ellis ES (1993). (1-Butyl-4-piperidinyl)methyl 8-amino-7-chloro-1,4-benzodioxane-5-carboxylate hydrochloride: a highly potent and selective 5-HT4 receptor antagonist derived from metoclopramide. American Chemical Society (Acs)  Journal of Medicinal Chemistry  vol. 36, (25) 4121-4123. 10.1021/jm00077a018

Wardle KA and Sanger GJ (1993). The guinea‐pig distal colon ‐ a sensitive preparation for the investigation of 5‐HT4 receptor‐mediated contractions. Wiley  British Journal of Pharmacology  vol. 110, (4) 1593-1599. 10.1111/j.1476-5381.1993.tb14006.x

King FD, Hadley MS, Joiner KT, Martin RT, Sanger GJ, Smith DM, Smith GE, Smith P, Turner DH and Watts EA (1993). Substituted benzamides with conformationally restricted side chains. 5. Azabicyclo[x.y.z] derivatives as 5-HT4 receptor agonists and gastric motility stimulants. American Chemical Society (Acs)  Journal of Medicinal Chemistry  vol. 36, (6) 683-689. 10.1021/jm00058a004

Blackburn TP, Baxter GS, Kennett GA, King FD, Piper DC, Sanger GJ, Thomas DR, Upton N and Wood MD (1993). BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties. Springer Nature  Psychopharmacology  vol. 110, (3) 257-264. 10.1007/bf02251279

Bermudez J, King FD and Sanger GJ (1992). Indazole and indoline as aromatic bioisosteres in the imidazole class of serotonin 5-HT3 receptor antagonists. Elsevier  Bioorganic & Medicinal Chemistry Letters  vol. 2, (12) 1509-1512. 10.1016/s0960-894x(00)80418-7

Bermudez J, Dunbar A, Sanger GJ and Turner DH (1990). Stimulation of Canine Gastric Motility by BRL 24924, a New Gastric Prokinetic Agent. Wiley  Neurogastroenterology & Motility  vol. 2, (4) 281-286. 10.1111/j.1365-2982.1990.tb00036.x

King FD, Dabbs S, Bermudez J and Sanger GJ (1990). Benzotriazinones as virtual ring mimics of o-methoxybenzamides: novel and potent 5-HT3 receptor antagonists. American Chemical Society (Acs)  Journal of Medicinal Chemistry  vol. 33, (11) 2942-2944. 10.1021/jm00173a002

Moss HE and Sanger GJ (1990). The effects of granisetron, ICS 205–930 and ondansetron on the visceral pain reflex induced by duodenal distension. Wiley  British Journal of Pharmacology  vol. 100, (3) 497-501. 10.1111/j.1476-5381.1990.tb15836.x

Bermudez J, Fake CS, Joiner GF, Joiner KA, King FD, Miner WD and Sanger GJ (1990). 5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives. American Chemical Society (Acs)  Journal of Medicinal Chemistry  vol. 33, (7) 1924-1929. 10.1021/jm00169a016

Bermudez J, Dunbar A, Sanger GJ and Turner DH (1990). Stimulation of canine gastric motility by BRL 24924, a new gastric prokinetic agent. Journal of Gastrointestinal Motility  vol. 2, (4) 281-286.

Wardle KA and Sanger GJ (1989). Atypical 5-HT receptors in guinea-pig isolated ileum. British Journal of Pharmacology  vol. 98 Suppl,

Sanger GJ and Nelson DR (1989). Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron). Elsevier  European Journal of Pharmacology  vol. 159, (2) 113-124. 10.1016/0014-2999(89)90695-x

King FD and Sanger GJ (1989). 5-HT3 RECEPTOR ANTAGONISTS. Portico  Drugs of The Future  vol. 14, (9) 10.1358/dof.1989.014.09.103408

Sanger GJ and King FD (1988). From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists. Drug Design and Discovery  vol. 3, (4) 273-295.

Bermudez J, Boyle E, Miner W and Sanger G (1988). The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Springer Nature  British Journal of Cancer  vol. 58, (5) 644-650. 10.1038/bjc.1988.277

Andrews PLR, Rapeport WG and Sanger GJ (1988). Neuropharmacology of emesis induced by anti-cancer therapy. Elsevier  Trends in Pharmacological Sciences  vol. 9, (9) 334-341. 10.1016/0165-6147(88)90106-x

Burke T and Sanger G (1988). Regionally selective cholinergic stimulation by BRL 24924 in the human isolated gut. Wiley  British Journal of Clinical Pharmacology  vol. 26, (3) 261-265. 10.1111/j.1365-2125.1988.tb05275.x

King FD and Sanger GJ (1988). Chapter 21. Gastrointestinal Motility Enhancing Agents. Elsevier  10.1016/s0065-7743(08)60849-0

Sanger GJ (1987). Increased gut cholinergic activity and antagonism of 5‐hydroxytryptamine M‐receptors by BRL 24924: potential clinical importance of BRL 24924. Wiley  British Journal of Pharmacology  vol. 91, (1) 77-87. 10.1111/j.1476-5381.1987.tb08985.x

SANGER GJ (1987). Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. Springer Nature [Academic Journals On Nature.Com]  British Journal of Cancer  vol. 56, 159-162. 10.1038/bjc.1987.177

Sanger GJ and McClelland CM (1986). Increased gastric cholinergic activity evoked by 5-hydroxy-L-tryptophan in the rat. Elsevier  European Journal of Pharmacology  vol. 127, (3) 179-185. 10.1016/0014-2999(86)90362-6

SANGER GJ and Miner WD (1986). Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Wiley  British Journal of Pharmacology  vol. 88, 497-499. 10.1111/j.1476-5381.1986.tb10228.x

Sanger GJ (1985). The effects of various pharmacological agents on the metoclopramide-induced increase in cholinergic-mediated contractions of rat isolated forestomach. Elsevier  European Journal of Pharmacology  vol. 114, (2) 139-145. 10.1016/0014-2999(85)90621-1

Sanger GJ (1984). Mechanisms by which Metoclopramide can Increase Gastrointestinal Motility. Mechanisms of Gastrointestinal Motility and Secretion  Springer Nature  10.1007/978-1-4684-4853-5_21

Sanger GJ and Bennett A (1984). Techniques for Studying Gastrointestinal Motility in Vitro. Mechanisms of Gastrointestinal Motility and Secretion  Springer Nature  10.1007/978-1-4684-4853-5_2

McRitchie B, McClelland CM, Cooper SM, Turner DH and Sanger GJ (1984). Dopamine Antagonists as Anti-Emetics and as Stimulants of Gastric Motility. Mechanisms of Gastrointestinal Motility and Secretion  Springer Nature  10.1007/978-1-4684-4853-5_20

Bennett A and Sanger GJ (1984). Relationships of Prostaglandins to Gastrointestinal Motility and Secretion. Mechanisms of Gastrointestinal Motility and Secretion  Springer Nature  10.1007/978-1-4684-4853-5_9

Bennett A, Sanger GJ, Stamford IF and Hensby CN (1983). Prostanoids formed by human gastrointestinal tissues and their effects on muscle activity. Advances in Prostaglandin, Thromboxane, and Leukotriene Research  vol. 12, 379-381.

BENNETT A and SANGER GJ (1982). PINANE THROMBOXANE A2 ANALOGUES ARE NON‐SELECTIVE PROSTANOID ANTAGONISTS IN RAT AND HUMAN STOMACH MUSCLE. Wiley  British Journal of Pharmacology  vol. 77, (4) 591-596. 10.1111/j.1476-5381.1982.tb09336.x

Sanger GJ, Jackson A and Bennett A (1982). A prostaglandin analogue which potently relaxes human uterus but not gut muscle. Elsevier  European Journal of Pharmacology  vol. 81, (1) 141-143. 10.1016/0014-2999(82)90613-6

BENNETT A, HENSBY CN, SANGER GJ and STAMFORD IF (1981). METABOLITES OF ARACHIDONIC ACID FORMED BY HUMAN GASTROINTESTINAL TISSUES AND THEIR ACTIONS ON THE MUSCLE LAYERS. Wiley  British Journal of Pharmacology  vol. 74, (2) 435-444. 10.1111/j.1476-5381.1981.tb09989.x

Bennet A, Hensby CN, Sanger GJ and Stamford IF (1981). Identification and Distribution of Arachidonic Acid Metabolites in the Human Gastrointestinal Tract, and the Ways in Which Some of these Affect the Longitudinal Muscle. The Prostaglandin System  Springer Nature  10.1007/978-1-4684-3896-3_27

Sanger GJ and Bennett A (1981). Prostanoid Agonists and Antagonists: Differentiation of Prostanoid Receptors in the Gut. The Prostaglandin System  Springer Nature  10.1007/978-1-4684-3896-3_28

BENNETT A, PRATT D and SANGER GJ (1980). ANTAGONISM BY FENAMATES OF PROSTAGLANDIN ACTION IN GUINEA‐PIG AND HUMAN ALIMENTARY MUSCLE. Wiley  British Journal of Pharmacology  vol. 68, (3) 357-362. 10.1111/j.1476-5381.1980.tb14548.x

Sanger GJ and Bennett A (1980). Trimethoquinol selectively antagonizes contractions of rat gastric fundus to TXB2 and epoxymethano analogs of PGH2. Advances in Prostaglandin, Thromboxane, and Leukotriene Research  vol. 8, 1559-1560.

Sanger GJ and Bennett A (1980). PGI2 or PGE2 selectively antagonize responses to excitatory PGs in human isolated myometrium. Advances in Prostaglandin, Thromboxane, and Leukotriene Research  vol. 6, 399-400.

Bennett A and Sanger GJ (1980). Prostacyclin relaxes the longitudinal muscle of human isolated stomach and antagonizes contractions to some prostanoids [proceedings]. The Journal of Physiology  vol. 298, 45p-46p.

Lacey SM and Sanger GJ (1980). Antagonism of prostanoid-induced contractions of rat stomach muscle by trimethoquinol or isoxsuprine. British Journal of Pharmacology  vol. 70, (1)

BENNETT A, JAROSIK C, SANGER GJ and WILSON DE (1980). ANTAGONISM OF PROSTANOID‐INDUCED CONTRACTIONS OF RAT GASTRIC FUNDUS MUSCLE BY SC‐19220, SODIUM MECLOFENAMATE, INDOMETHACIN OR TRIMETHOQUINOL. Wiley  British Journal of Pharmacology  vol. 71, (1) 169-175. 10.1111/j.1476-5381.1980.tb10922.x

Sanger GJ and Bennett A (1979). Fenamates may antagonize the actions of prostaglandin endoperoxides in human myometrium. Wiley  British Journal of Clinical Pharmacology  vol. 8, (5) 479-482. 10.1111/j.1365-2125.1979.tb01030.x

Bennett A, Carroll MA and Sanger GJ (1979). Sodium flufenamate antagonises the potentiation by prostaglandins of noradrenaline-induced vasoconstriction in rat mesentery [proceedings]. British Journal of Pharmacology  vol. 66, (3)

Bennett A and Sanger GJ (1979). Trimethoquinol selectively antagonises longitudinal muscle contractions of rat isolated gastric fundus to thromboxane B2 and epoxymethano analogues of PGH2 [proceedings]. British Journal of Pharmacology  vol. 66, (3)

Bennett A and Sanger GJ (1979). Prostacyclin and prostaglandin E2 selectively antagonize responses of human isolated myometrium to excitatory prostaglandins [proceedings]. The Journal of Physiology  vol. 292, 36p-37p.

Bennett A and Sanger GJ (1978). The effects of prostaglandin D2 on the circular muscle of guinea-pig isolated ileum and colon [proceedings]. British Journal of Pharmacology  vol. 63, (2) 357p-358p.

Sanger GJ and Watt AJ (1976). A postsynaptic action of prostaglandin E1 on sympathetic responses in guinea-pig ileum [proceedings]. British Journal of Pharmacology  vol. 58, (2) 290p-291p.

Blair EL, Grund ER, Reed JD, Sanders DJ, Sanger G and Shaw B (1975). The effect of sympathetic nerve stimulation on serum gastrin, gastric acid secretion and mucosal blood flow responses to meat extract stimulation in anaesthetized cats. Wiley  The Journal of Physiology  vol. 253, (2) 493-504. 10.1113/jphysiol.1975.sp011202